{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T10:08:01Z","timestamp":1794737281976,"version":"4.9.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Global Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>New antibiotics active against multidrug resistant bacteria (MDR-B) are licensed by regulatory agencies based on pivotal trials that serve the primary purpose of obtaining marketing-authorization. There is increasing concern that they do not offer guidance on how to best use new antibiotics, in which population, and to what extent they overcome existing resistance. We reviewed the literature for pre-approval studies (phase 2 and 3 randomized controlled trials) and post-approval studies (randomized and non-randomized controlled trials) evaluating efficacy and safety of new antibiotics, classified by WHO as Reserve, approved in the European Union and the US from January 2010 to May 2023. Substantial failures occur in generating evidence to guide routine clinical use: preapproval studies lack representativeness, select outcomes and comparators to chase statistical significance, and often avoid using prespecified analytical methods. Three recommendations are key to enhance the quality and relevance of clinical data underpinning use of last resort molecules on the WHO AWaRe Reserve list active against carbapenem-resistant MDR-B i). separation of pivotal trials from post-approval studies, which should be funded by public programs and de-linked from commercial purposes, ii). development and maintenance of a global infrastructure to conduct post-approval public health focused studies, and iii). development of trial platforms that use efficient, adaptive designs to inform clinical decision making and country level technology appraisal. These solutions will allow clinicians to determine whether recently approved Reserve antibiotics are not only \u201cnewer\u201d but also \u201cbetter\u201d for vulnerable patient populations at particular risk for infections by MDR-B.<\/jats:p>","DOI":"10.1186\/s12992-025-01109-4","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T10:42:15Z","timestamp":1743763335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Reserve antibiotics: overcoming limitations of evidence generated from regulatory approval trials"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6680-6507","authenticated-orcid":false,"given":"Lorenzo","family":"Moja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlieke EA","family":"de Kraker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Zanichelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loice Achieng","family":"Ombajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sharland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"10325","key":"1109_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"C Antimicrobial Resistance","year":"2022","unstructured":"Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"issue":"10","key":"1109_CR2","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cmi.2017.09.001","volume":"23","author":"H Wright","year":"2017","unstructured":"Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false Dawn?? Clin Microbiol Infect. 2017;23(10):704\u201312.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"1109_CR3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","volume":"23","author":"M Abbas","year":"2017","unstructured":"Abbas M, Paul M, Huttner A. New and improved? A review of novel antibiotics for Gram-positive bacteria. Clin Microbiol Infect. 2017;23(10):697\u2013703.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"1109_CR4","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMp1905589","volume":"381","author":"TB Nielsen","year":"2019","unstructured":"Nielsen TB, et al. Sustainable discovery and development of Antibiotics - Is a nonprofit approach the future?? N Engl J Med. 2019;381(6):503\u20135.","journal-title":"N Engl J Med"},{"issue":"3","key":"1109_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.healthpol.2020.11.015","volume":"125","author":"D Gotham","year":"2021","unstructured":"Gotham D, et al. Reimbursement models to tackle market failures for antimicrobials: approaches taken in France, Germany, Sweden, the united Kingdom, and the united States. Health Policy. 2021;125(3):296\u2013306.","journal-title":"Health Policy"},{"key":"1109_CR6","unstructured":"World Health Organization. WHO model list of essential medicines. 20th list. World Health Organization: Geneva; 2017."},{"issue":"1","key":"1109_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1473-3099(17)30724-7","volume":"18","author":"M Sharland","year":"2018","unstructured":"Sharland M, et al. Classifying antibiotics in the WHO essential medicines list for optimal use-be aware. Lancet Infect Dis. 2018;18(1):18\u201320.","journal-title":"Lancet Infect Dis"},{"issue":"Suppl 2","key":"1109_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2024.02.003","volume":"30","author":"L Moja","year":"2024","unstructured":"Moja L, et al. WHO\u2019s essential medicines and aware: recommendations on first- and second-choice antibiotics for empiric treatment of clinical infections. Clin Microbiol Infect. 2024;30(Suppl 2):S1\u201351.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"1109_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"},{"key":"1109_CR10","unstructured":"Tamma PD, et al. IDSA guidance on the treatment of Antimicrobial-Resistant Gram-Negative infections: version 1.0. Infectious Diseases Society of America; 2020."},{"key":"1109_CR11","doi-asserted-by":"crossref","unstructured":"Paul M, et al. European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European society of intensive care Medicine). Clin Microbiol Infect; 2021.","DOI":"10.1016\/j.cmi.2021.11.025"},{"key":"1109_CR12","unstructured":"World Health Organization. The WHO Essential Medicines List Antibiotic Book: Improving antibiotic AWaReness\u2026 2021 27.01.2022]; Available from: https:\/\/www.who.int\/publications\/m\/item\/the-who-essential-medicines-list-antibiotic-book-improving-antibiotic-awareness, Accessed 27.01.2022]."},{"issue":"12","key":"1109_CR13","doi-asserted-by":"publisher","first-page":"e032592","DOI":"10.1136\/bmjopen-2019-032592","volume":"9","author":"L Folgori","year":"2019","unstructured":"Folgori L, et al. Standardising neonatal and paediatric antibiotic clinical trial design and conduct: the PENTA-ID network view. BMJ Open. 2019;9(12):e032592.","journal-title":"BMJ Open"},{"issue":"12","key":"1109_CR14","doi-asserted-by":"publisher","first-page":"e444","DOI":"10.1016\/S1473-3099(19)30284-1","volume":"19","author":"S Lanini","year":"2019","unstructured":"Lanini S, et al. Non-inferiority versus superiority trial design for new antibiotics in an era of high antimicrobial resistance: the case for post-marketing, adaptive randomised controlled trials. Lancet Infect Dis. 2019;19(12):e444\u201351.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"1109_CR15","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1093\/cid\/ciaa457","volume":"72","author":"D Yahav","year":"2021","unstructured":"Yahav D, Tau N, Shepshelovich D. Assessment of data supporting the efficacy of new antibiotics for treating infections caused by Multidrug-resistant bacteria. Clin Infect Dis. 2021;72(11):1968\u201374.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1109_CR16","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/cid\/ciaa463","volume":"72","author":"JH Powers","year":"2021","unstructured":"Powers JH. Improving the evidence for new interventions in infectious diseases: refocusing on patients instead of pathogens and direct evidence for added patient benefits. Clin Infect Dis. 2021;72(11):1975\u20138.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1109_CR17","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/infdis\/jiaa536","volume":"223","author":"MS Sinha","year":"2021","unstructured":"Sinha MS, Powers JH, Kesselheim AS. The wrong cure: financial incentives for unimpressive new antibiotics. J Infect Dis. 2021;223(9):1506\u20139.","journal-title":"J Infect Dis"},{"issue":"12","key":"1109_CR18","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S1473-3099(19)30532-8","volume":"19","author":"M Sharland","year":"2019","unstructured":"Sharland M, et al. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 essential medicines list becomes a global antibiotic stewardship tool. Lancet Infect Dis. 2019;19(12):1278\u201380.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"1109_CR19","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.cmi.2022.03.014","volume":"28","author":"G Sulis","year":"2022","unstructured":"Sulis G, et al. Exposure to world health organization\u2019s aware antibiotics and isolation of multidrug resistant bacteria: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(9):1193\u2013202.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"1109_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, et al. Efficacy and safety of Cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021;21(2):226\u201340.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1109_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1056\/NEJMc1807634","volume":"380","author":"JA McKinnell","year":"2019","unstructured":"McKinnell JA, et al. Plazomicin for infections caused by Carbapenem-Resistant Enterobacteriaceae. N Engl J Med. 2019;380(8):791\u20133.","journal-title":"N Engl J Med"},{"issue":"9","key":"1109_CR22","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciz530","volume":"70","author":"J Motsch","year":"2020","unstructured":"Motsch J, et al. RESTORE-IMI 1: A multicenter, randomized, Double-blind trial comparing efficacy and safety of Imipenem\/Relebactam vs colistin plus Imipenem in patients with Imipenem-nonsusceptible bacterial infections. Clin Infect Dis. 2020;70(9):1799\u2013808.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1109_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","volume":"7","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG, et al. Effect and safety of Meropenem-Vaborbactam versus Best-Available therapy in patients with Carbapenem-Resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7(4):439\u201355.","journal-title":"Infect Dis Ther"},{"issue":"8","key":"1109_CR24","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/INF.0000000000002392","volume":"38","author":"JS Bradley","year":"2019","unstructured":"Bradley JS, et al. Safety and efficacy of Ceftazidime-Avibactam plus metronidazole in the treatment of children >\/=3 months to <\u200918 years with complicated Intra-Abdominal infection: results from a phase 2, randomized, controlled trial. Pediatr Infect Dis J. 2019;38(8):816\u201324.","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"1109_CR25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/INF.0000000000002395","volume":"38","author":"JS Bradley","year":"2019","unstructured":"Bradley JS, et al. Safety and efficacy of Ceftazidime-Avibactam in the treatment of children >\/=3 months to <\u200918 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial. Pediatr Infect Dis J. 2019;38(9):920\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"1109_CR26","doi-asserted-by":"publisher","first-page":"e1001502","DOI":"10.1371\/journal.pmed.1001502","volume":"10","author":"GJ Chan","year":"2013","unstructured":"Chan GJ, et al. Risk of early-onset neonatal infection with maternal infection or colonization: a global systematic review and meta-analysis. PLoS Med. 2013;10(8):e1001502.","journal-title":"PLoS Med"},{"issue":"9","key":"1109_CR27","doi-asserted-by":"publisher","first-page":"e1003681","DOI":"10.1371\/journal.pmed.1003681","volume":"18","author":"BT Huynh","year":"2021","unstructured":"Huynh BT, et al. Severe bacterial neonatal infections in Madagascar, Senegal, and Cambodia: A multicentric community-based cohort study. PLoS Med. 2021;18(9):e1003681.","journal-title":"PLoS Med"},{"issue":"1","key":"1109_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/archdischild-2019-316816","volume":"105","author":"G Li","year":"2020","unstructured":"Li G, et al. Towards Understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network. Arch Dis Child. 2020;105(1):26\u201331.","journal-title":"Arch Dis Child"},{"issue":"12","key":"1109_CR29","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S1473-3099(21)00050-5","volume":"21","author":"KM Thomson","year":"2021","unstructured":"Thomson KM, et al. Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). Lancet Infect Dis. 2021;21(12):1677\u201388.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1109_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13756-021-00897-9","volume":"10","author":"J Tumuhamye","year":"2021","unstructured":"Tumuhamye J, et al. Vaginal colonization with antimicrobial-resistant bacteria among women in labor in central Uganda: prevalence and associated factors. Antimicrob Resist Infect Control. 2021;10(1):37.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"7","key":"1109_CR31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2174\/138945012800675777","volume":"13","author":"W Zingg","year":"2012","unstructured":"Zingg W, Posfay-Barbe KM. Antibiotic use in children - off-label use. Curr Drug Targets. 2012;13(7):885\u201392.","journal-title":"Curr Drug Targets"},{"issue":"2","key":"1109_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/jgs.13250","volume":"63","author":"T Avni","year":"2015","unstructured":"Avni T, et al. Participation of elderly adults in randomized controlled trials addressing antibiotic treatment of pneumonia. J Am Geriatr Soc. 2015;63(2):233\u201343.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1109_CR33","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"A Cassini","year":"2019","unstructured":"Cassini A, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56\u201366.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1109_CR34","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1186\/cc12734","volume":"17","author":"YE Claessens","year":"2013","unstructured":"Claessens YE, et al. Are clinical trials dealing with severe infection fitting routine practices? Insights from a large registry. Crit Care. 2013;17(3):R89.","journal-title":"Crit Care"},{"issue":"1","key":"1109_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12879-021-05995-y","volume":"21","author":"V Daitch","year":"2021","unstructured":"Daitch V, et al. Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity. BMC Infect Dis. 2021;21(1):309.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"1109_CR36","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s00134-017-4802-4","volume":"43","author":"JF Timsit","year":"2017","unstructured":"Timsit JF, et al. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE\u2019s STAT-Net. Intensive Care Med. 2017;43(7):1002\u201312.","journal-title":"Intensive Care Med"},{"issue":"6","key":"1109_CR37","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S1473-3099(20)30791-X","volume":"21","author":"AS Walker","year":"2021","unstructured":"Walker AS, et al. Personalised randomised controlled trial designs-a new paradigm to define optimal treatments for carbapenem-resistant infections. Lancet Infect Dis. 2021;21(6):e175\u201381.","journal-title":"Lancet Infect Dis"},{"key":"1109_CR38","doi-asserted-by":"publisher","first-page":"e1119","DOI":"10.1136\/bmj.e1119","volume":"344","author":"A Hrobjartsson","year":"2012","unstructured":"Hrobjartsson A, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ. 2012;344:e1119.","journal-title":"BMJ"},{"issue":"1","key":"1109_CR39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13063-017-1870-2","volume":"18","author":"C Heneghan","year":"2017","unstructured":"Heneghan C, Goldacre B, Mahtani KR. Why clinical trial outcomes fail to translate into benefits for patients. Trials. 2017;18(1):122.","journal-title":"Trials"},{"issue":"9981","key":"1109_CR40","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, et al. Ceftolozane-tazobactam compared with Levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385(9981):1949\u201356.","journal-title":"Lancet"},{"issue":"8","key":"1109_CR41","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS, et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788\u201399.","journal-title":"JAMA"},{"issue":"6","key":"1109_CR42","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/QCO.0000000000000681","volume":"33","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Portunato F, Roberts JA. Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base. Curr Opin Infect Dis. 2020;33(6):501\u201310.","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"1109_CR43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(2):213\u201325.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1109_CR44","doi-asserted-by":"publisher","first-page":"e000227","DOI":"10.1136\/bmjmed-2022-000227","volume":"1","author":"M Mitra-Majumdar","year":"2022","unstructured":"Mitra-Majumdar M, et al. Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs. BMJ Med. 2022;1(1):e000227.","journal-title":"BMJ Med"},{"issue":"14","key":"1109_CR45","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","volume":"367","author":"RJ Little","year":"2012","unstructured":"Little RJ, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355\u201360.","journal-title":"N Engl J Med"},{"issue":"1","key":"1109_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/cid\/cix246","volume":"65","author":"JH Rex","year":"2017","unstructured":"Rex JH, et al. Progress in the fight against Multidrug-Resistant bacteria 2005\u20132016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. Clin Infect Dis. 2017;65(1):141\u20136.","journal-title":"Clin Infect Dis"},{"key":"1109_CR47","unstructured":"European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. 2022 June 10, 2024]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf"},{"issue":"6","key":"1109_CR48","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","volume":"63","author":"FM Wagenlehner","year":"2016","unstructured":"Wagenlehner FM, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis. 2016;63(6):754\u201362.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1109_CR49","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/jlme.12079","volume":"41","author":"K Outterson","year":"2013","unstructured":"Outterson K, et al. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980\u20132009. J Law Med Ethics. 2013;41(3):688\u201396.","journal-title":"J Law Med Ethics"},{"key":"1109_CR50","doi-asserted-by":"publisher","first-page":"k587","DOI":"10.1136\/bmj.k587","volume":"360","author":"JH Powers","year":"2018","unstructured":"Powers JH, Evans SR, Kesselheim AS. Studying new antibiotics for multidrug resistant infections: are today\u2019s patients paying for unproved future benefits? BMJ. 2018;360:k587.","journal-title":"BMJ"},{"issue":"1","key":"1109_CR51","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1186\/s12879-019-4409-1","volume":"19","author":"BM Alraddadi","year":"2019","unstructured":"Alraddadi BM, et al. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae. BMC Infect Dis. 2019;19(1):772.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"1109_CR52","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","volume":"68","author":"M Tumbarello","year":"2019","unstructured":"Tumbarello M, et al. Efficacy of Ceftazidime-Avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355\u201364.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1109_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","volume":"66","author":"D van Duin","year":"2018","unstructured":"van Duin D, et al. Colistin versus Ceftazidime-Avibactam in the treatment of infections due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163\u201371.","journal-title":"Clin Infect Dis"},{"key":"1109_CR54","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Cruz A et al. A Case-Control study of Real-Life experience with Ceftolozane-Tazobactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection. Antimicrob Agents Chemother, 2019. 63(2).","DOI":"10.1128\/AAC.02340-18"},{"issue":"2","key":"1109_CR55","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/cid\/ciz816","volume":"71","author":"JM Pogue","year":"2020","unstructured":"Pogue JM, et al. Ceftolozane\/Tazobactam vs polymyxin or Aminoglycoside-based regimens for the treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020;71(2):304\u201310.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1109_CR56","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/jac\/dkab163","volume":"76","author":"D Shepshelovich","year":"2021","unstructured":"Shepshelovich D, et al. Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. J Antimicrob Chemother. 2021;76(9):2415\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"1109_CR57","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/cid\/cis688","volume":"55","author":"Infectious Diseases Society of","year":"2012","unstructured":"Infectious Diseases Society of. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis. 2012;55(8):1031\u201346.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"1109_CR58","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1093\/cid\/ciaa930","volume":"72","author":"M Paul","year":"2021","unstructured":"Paul M, et al. Investigator-initiated randomized controlled trials in infectious diseases: better value for money for registration trials of new antimicrobials. Clin Infect Dis. 2021;72(7):1259\u201364.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1109_CR59","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jama.2007.26","volume":"299","author":"SH Woolf","year":"2008","unstructured":"Woolf SH. The meaning of translational research and why it matters. JAMA. 2008;299(2):211\u20133.","journal-title":"JAMA"},{"issue":"4","key":"1109_CR60","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S2468-2667(22)00057-3","volume":"7","author":"HJ Sch\u00fcnemann","year":"2022","unstructured":"Sch\u00fcnemann HJ, et al. The ecosystem of health decision making: from fragmentation to synergy. Lancet Public Health. 2022;7(4):e378\u201390.","journal-title":"Lancet Public Health"},{"issue":"7","key":"1109_CR61","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41429-020-0300-y","volume":"73","author":"CM Morel","year":"2020","unstructured":"Morel CM, et al. Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus. J Antibiot (Tokyo). 2020;73(7):421\u20138.","journal-title":"J Antibiot (Tokyo)"},{"key":"1109_CR62","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1038\/d41586-020-02884-3","volume":"586","author":"B Plackett","year":"2020","unstructured":"Plackett B. Why big pharma has abandoned antibiotics. Nature. 2020;586:S50\u20132.","journal-title":"Nature"},{"issue":"10","key":"1109_CR63","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/17460441.2018.1515908","volume":"13","author":"M Renwick","year":"2018","unstructured":"Renwick M, Mossialos E. What are the economic barriers of antibiotic R&D and how can we overcome them? Expert Opin Drug Discov. 2018;13(10):889\u201392.","journal-title":"Expert Opin Drug Discov"},{"key":"1109_CR64","doi-asserted-by":"crossref","unstructured":"Wright H, Harris PNA, Chatfield MD, Lye D, Henderson A, Harris-Brown T, et al. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Trials. 2021;22(1):889. https:\/\/doi.org\/10.1186\/s13063-021-05870-w. PMID: 34876196; PMCID: PMC8649313.","DOI":"10.1186\/s13063-021-05870-w"},{"issue":"7","key":"1109_CR65","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1128\/AAC.00638-15","volume":"59","author":"E Bettiol","year":"2015","unstructured":"Bettiol E, et al. Challenges and solutions for clinical development of new antibacterial agents: results of a survey among pharmaceutical industry professionals. Antimicrob Agents Chemother. 2015;59(7):3695\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"1109_CR66","doi-asserted-by":"publisher","first-page":"ofaa464","DOI":"10.1093\/ofid\/ofaa464","volume":"7","author":"CJ Clancy","year":"2020","unstructured":"Clancy CJ, Nguyen MH. Buying time: the AMR action fund and the state of antibiotic development in the united states 2020. Open Forum Infect Dis. 2020;7(11):ofaa464.","journal-title":"Open Forum Infect Dis"},{"key":"1109_CR67","doi-asserted-by":"publisher","first-page":"106625","DOI":"10.1016\/j.cct.2021.106625","volume":"112","author":"AM Vanderbeek","year":"2022","unstructured":"Vanderbeek AM, et al. Implementation of platform trials in the COVID-19 pandemic: A rapid review. Contemp Clin Trials. 2022;112:106625.","journal-title":"Contemp Clin Trials"},{"key":"1109_CR68","doi-asserted-by":"publisher","first-page":"100901","DOI":"10.1016\/j.jbior.2022.100901","volume":"86","author":"L Peto","year":"2022","unstructured":"Peto L, Horby P, Landray M. Establishing COVID-19 trials at scale and Pace: experience from the RECOVERY trial. Adv Biol Regul. 2022;86:100901.","journal-title":"Adv Biol Regul"},{"key":"1109_CR69","doi-asserted-by":"crossref","unstructured":"Hassoun-Kheir N, et al. Perpetual observational studies: new strategies to support efficient implementation of observational studies and randomized trials in infectious diseases. Clin Microbiol Infect; 2022.","DOI":"10.1016\/j.cmi.2022.07.024"},{"issue":"12","key":"1109_CR70","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1093\/cid\/ciy516","volume":"67","author":"MEA de Kraker","year":"2018","unstructured":"de Kraker MEA, et al. Optimizing the design and analysis of clinical trials for antibacterials against Multidrug-resistant organisms: A white paper from COMBACTE\u2019s STAT-Net. Clin Infect Dis. 2018;67(12):1922\u201331.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1109_CR71","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/cid\/civ495","volume":"61","author":"SR Evans","year":"2015","unstructured":"Evans SR, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis. 2015;61(5):800\u20136.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"1109_CR72","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/cid\/cix571","volume":"65","author":"JS Solomkin","year":"2017","unstructured":"Solomkin JS. A cool reception for desirability of outcome ranking (DOOR)\/Response adjusted for duration of antibiotic risk (RADAR) in Intra-abdominal infections. Clin Infect Dis. 2017;65(9):1580\u20131.","journal-title":"Clin Infect Dis"},{"key":"1109_CR73","doi-asserted-by":"crossref","unstructured":"ISRCTN48721236. NeoSep1: a study to determine the ranking of existing and new antibiotics combinations to treat newborn babies who are in hospital with severe sepsis. ISRCTN Registry https:\/\/doi.org\/10.1186\/ISRCTN48721236","DOI":"10.1186\/ISRCTN48721236"},{"key":"1109_CR74","unstructured":"Rossel A, et al. How representative is a point-of-care randomized trial? Clinical outcomes of patients excluded from a point-of-care randomized controlled trial evaluating antibiotic duration for Gram-negative bacteraemia: a multicentre prospective observational cohort study. Clin Microbiol Infect; 2021."},{"issue":"2","key":"1109_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cmi.2016.07.029","volume":"23","author":"A Huttner","year":"2017","unstructured":"Huttner A, et al. Closing the evidence gap in infectious disease: point-of-care randomization and informed consent. Clin Microbiol Infect. 2017;23(2):73\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"1109_CR76","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/cid\/ciaa061","volume":"72","author":"JR Strich","year":"2021","unstructured":"Strich JR, et al. Pharmacoepidemiology of Ceftazidime-Avibactam use: A retrospective cohort analysis of 210 US hospitals. Clin Infect Dis. 2021;72(4):611\u201321.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1109_CR77","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s40121-021-00412-y","volume":"10","author":"D Yahav","year":"2021","unstructured":"Yahav D, Shepshelovich D, Tau N. Cost analysis of new antibiotics to treat Multidrug-Resistant bacterial infections: Mind the gap. Infect Dis Ther. 2021;10(1):621\u201330.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"1109_CR78","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661\u201373.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"1109_CR79","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","volume":"19","author":"MH Kollef","year":"2019","unstructured":"Kollef MH, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299\u2013311.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"1109_CR80","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, et al. Efficacy and safety of Ceftazidime-Avibactam plus metronidazole versus meropenem in the treatment of complicated Intra-abdominal infection: results from a randomized, controlled, Double-Blind, phase 3 program. Clin Infect Dis. 2016;62(11):1380\u20139.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1109_CR81","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","volume":"49","author":"X Qin","year":"2017","unstructured":"Qin X, et al. A randomised, double-blind, phase 3 study comparing the efficacy and safety of Ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. Int J Antimicrob Agents. 2017;49(5):579\u201388.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"1109_CR82","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","volume":"60","author":"J Solomkin","year":"2015","unstructured":"Solomkin J, et al. Ceftolozane\/Tazobactam plus metronidazole for complicated Intra-abdominal infections in an era of multidrug resistance: results from a randomized, Double-Blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60(10):1462\u201371.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1109_CR83","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","volume":"152","author":"J Solomkin","year":"2017","unstructured":"Solomkin J, et al. Assessing the efficacy and safety of Eravacycline vs ertapenem in complicated Intra-abdominal infections in the investigating Gram-Negative infections treated with Eravacycline (IGNITE 1) trial: A randomized clinical trial. JAMA Surg. 2017;152(3):224\u201332.","journal-title":"JAMA Surg"},{"issue":"6","key":"1109_CR84","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/ciy1029","volume":"69","author":"JS Solomkin","year":"2019","unstructured":"Solomkin JS, et al. IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of Eravacycline vs meropenem in the treatment of complicated intraabdominal infections. Clin Infect Dis. 2019;69(6):921\u20139.","journal-title":"Clin Infect Dis"},{"key":"1109_CR85","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ijid.2022.08.003","volume":"123","author":"Y Sun","year":"2022","unstructured":"Sun Y, et al. A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of Ceftolozane\/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections. Int J Infect Dis. 2022;123:157\u201365.","journal-title":"Int J Infect Dis"},{"key":"1109_CR86","doi-asserted-by":"crossref","unstructured":"Titov I, et al. Double-blind, multicenter trial comparing efficacy and safety of Imipenem\/Cilastatin\/Relebactam versus Piperacillin\/Tazobactam in adults with Hospital-acquired or Ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis; 2020. A Randomized.","DOI":"10.1093\/cid\/ciaa803"},{"issue":"3","key":"1109_CR87","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285\u201395.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"1109_CR88","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMoa1801467","volume":"380","author":"FME Wagenlehner","year":"2019","unstructured":"Wagenlehner FME, et al. Once-Daily Plazomicin for complicated urinary tract infections. N Engl J Med. 2019;380(8):729\u201340.","journal-title":"N Engl J Med"}],"container-title":["Globalization and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12992-025-01109-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12992-025-01109-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12992-025-01109-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T11:35:57Z","timestamp":1743852957000},"score":1,"resource":{"primary":{"URL":"https:\/\/globalizationandhealth.biomedcentral.com\/articles\/10.1186\/s12992-025-01109-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1109"],"URL":"https:\/\/doi.org\/10.1186\/s12992-025-01109-4","relation":{},"ISSN":["1744-8603"],"issn-type":[{"value":"1744-8603","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}